Marksans Pharma bags approval for Bells Healthcare All in One Oral Solution

22 Feb 2022 , 04:05 PM

Marksans Pharma Limited announced that its wholly-owned subsidiary Bell Sons & Co. (Druggists) Limited has received market authorization from UK MHRA for Bells Healthcare All in One Oral Solution.

Each 20 ml dose contains Paracetamol Ph. Eur. 500.0 mg, Guaifenesin Ph. Eur. 200.0 mg and Phenylephrine Hydrochloride Ph. Eur. 10.0 mg.
Therapeutic use of the product is for short-term symptomatic relief of colds, chills, and influenza including chesty coughs.

This is the first generic approval by UK MHRA for the product.

Marksans will manufacture the products at its UK MHRA approved facility Bell Sons & Co. (Druggists) Limited in the UK.

Marksans Pharma is headquartered at Mumbai, India and engages in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.

Marksans Pharma ended at Rs48.25 against its previous closing price of Rs49.65, down by Rs.1.40 or 2.82%.